Skip to main content

Table 1 Inclusion criteria

From: A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

1) Adults (≥18 years old),
2) Confirmed SARS-CoV-2 infection based on a positive RT-PCR test
3) Requiring in-hospital care
4) Imaging study compatible with pneumonia,
5) At least one of the following criteria
a). Dyspnea
 b). Lung infiltrates occupying > 50% of lung fields by CT scan
 c) PaO2/FiO2 ratio < 300 mmHg
 d). Peripheral oxygen saturation (SpO2) < 90% while breathing room air, a ≥ 3% drop in baseline SpO2, or the need of increased flow rates of supplemental oxygen in the case of chronic hypoxia; and the need for supplemental oxygen therapy according to the treating medical team’s judgment.
 e). Alteration of one or more of the following laboratory parameters
   D-dimer > 1 μg/mL
   Ferritin level > 300 ng/mL
   C-reactive protein (CRP) > 3 mg/L
   Lactate dehydrogenase (LDH) > 245 U/L
   Lymphopenia, defined as < 800 lymphocytes/uL
   Creatine kinase (CK) level > 800 IU/L